Get the Stockscreener App
1.17
7.14%
-0.09
After Hours:
1.21
0.04
+3.42%
Pacific Biosciences Of California Inc stock is traded at $1.17, with a volume of 9.48M.
It is down -7.14% in the last 24 hours and down -3.31% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.26
Open:
$1.26
24h Volume:
9.48M
Relative Volume:
1.22
Market Cap:
$351.43M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.78
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-7.87%
1M Performance:
-3.31%
6M Performance:
-8.59%
1Y Performance:
-35.00%
1-Day Range:
$1.16
$1.26
1-Week Range:
$1.16
$1.32
52-Week Range:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.17 | 366.45M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
133.73 | 225.15B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.71 | 155.92B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
383.34 | 146.41B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
94.03 | 118.42B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
77.57 | 45.96B | 5.69B | 1.41B | 577.90M | 6.95 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today - sharewise.com
Nuveen LLC Takes Position in Pacific Biosciences of California, Inc. $PACB - MarketBeat
2025 Microbiome SMRT Grant Awardees - PacBio
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Pacific Biosciences of California, Inc. $PACB Stock Position Raised by Invesco Ltd. - MarketBeat
Edmond DE Rothschild Holding S.A. Boosts Stock Position in Pacific Biosciences of California, Inc. $PACB - MarketBeat
Fibonacci Retracement Aligns with Support in Pacific Biosciences of California Inc.Market Sentiment Review & Community Shared Stock Ideas - beatles.ru
Will Pacific Biosciences of California Inc. bounce back from current supportMarket Risk Summary & Stepwise Trade Execution Plans - Newser
Quantitative breakdown of Pacific Biosciences of California Inc. recent moveEarnings Miss & Real-Time Sentiment Analysis - Newser
What’s the profit margin of Pacific Biosciences of California Inc.Price Action & Expert-Curated Trade Recommendations - خودرو بانک
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq - sharewise.com
Case Study: HiFi sequencing fast-tracks antimicrobial resistance research: 2x publications in half the time - PacBio
Will a bounce in Pacific Biosciences of California Inc. offer an exitJuly 2025 Opening Moves & Fast Entry and Exit Trade Plans - Newser
Visual analytics tools that track Pacific Biosciences of California Inc. performancePortfolio Risk Report & Weekly High Potential Alerts - Newser
What MACD and RSI say about Pacific Biosciences of California Inc.2025 Big Picture & Short-Term High Return Strategies - Newser
Powered by PacBio: Selected publications from August 2025 - PacBio
Pacific Biosciences shares rise 1.35% premarket after partnering with EpiCypher for novel insights in chromatin biology. - AInvest
Will Pacific Biosciences of California Inc. benefit from seasonality2025 Geopolitical Influence & Proven Capital Preservation Tips - خودرو بانک
PacBio and EpiCypher partner on chromatin analysis technology By Investing.com - Investing.com Canada
Is Pacific Biosciences of California Inc. stock bottoming outJuly 2025 Final Week & Real-Time Stock Price Movement Reports - Newser
Will Pacific Biosciences of California Inc. benefit from macro trendsWeekly Trade Report & Community Shared Stock Ideas - Newser
Volatility clustering patterns for Pacific Biosciences of California Inc.CEO Change & Short-Term High Return Ideas - Newser
What is Pacific Biosciences of California Inc. s P E ratio telling usJuly 2025 Technicals & Fast Entry and Exit Trade Plans - خودرو بانک
Signal strength of Pacific Biosciences of California Inc. stock in tech scannersQuarterly Portfolio Review & Reliable Volume Spike Trade Alerts - Newser
PacBio and EpiCypher partner on chromatin analysis technology - Investing.com
PacBio and EpiCypher Collaborate to Enhance Fiber-seq Assays with CUTANA Hia5 Enzyme for Improved Insights into Chromatin Biology - Quiver Quantitative
Single-Molecule DNA Analysis Breakthrough: PacBio and EpiCypher Unite for Revolutionary Fiber-seq Technology - Stock Titan
Pacific Biosciences Of California, Inc. shares rise 1.56% premarket after FDA approved breakthrough therapies for aggressive malignancies. - AInvest
PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow - Yahoo Finance
How to escape a deep drawdown in Pacific Biosciences of California Inc.Buy Signal & Growth Oriented Trade Recommendations - Newser
Is Pacific Biosciences of California Inc. trending in predictive chart modelsWeekly Trading Summary & High Accuracy Trade Alerts - Newser
Is Pacific Biosciences of California Inc. a defensive stockWeekly Profit Summary & Weekly Market Pulse Alerts - خودرو بانک
Does Pacific Biosciences of California Inc. have pricing powerTrade Entry Summary & Community Consensus Picks - خودرو بانک
Relative strength of Pacific Biosciences of California Inc. in sector analysisPortfolio Risk Report & Real-Time Volume Spike Alerts - Newser
Is Pacific Biosciences of California Inc. affected by consumer sentimentWeekly Gains Report & Stock Timing and Entry Methods - خودرو بانک
Market Trends: Is Pacific Biosciences of California Inc. a defensive stockPortfolio Performance Summary & Real-Time Volume Triggers - خودرو بانک
Can Pacific Biosciences of California Inc. hit a new high this monthMarket Trend Report & Growth Focused Entry Reports - Newser
Published on: 2025-09-02 10:17:32 - Newser
Is Pacific Biosciences of California Inc. stock a good pick for beginners2025 Price Action Summary & Verified Swing Trading Watchlists - خودرو بانک
What high frequency data says about Pacific Biosciences of California Inc.Dividend Hike & Weekly Breakout Watchlists - Newser
Street Watch: What’s next for Pacific Biosciences of California Inc. stockMarket Movement Recap & Weekly Consistent Profit Watchlists - خودرو بانک
What drives Pacific Biosciences of California Inc.’s stock priceLayoff News & Expert-Curated Trade Recommendations - خودرو بانک
Chart Patterns Forming a Bullish Setup in Pacific Biosciences of California Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Can momentum traders help lift Pacific Biosciences of California Inc.July 2025 Catalysts & Safe Capital Investment Plans - Newser
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):